Ivonescimab's BLA acceptance is a milestone for PD-1/VEGF bispecific antibodies in the U.S., potentially transforming ...

A Glasgow grandad has become the first patient in Scotland to undergo a major lung cancer trial.

Summit Therapeutics nears a 2026 FDA decision for ivonescimab with $710M cash and Akesobio catalysts. Find out why SMMT stock is upgraded to hold.

EAST LANSING, Mich. (WLNS) — As a person who has struggled with a cigarette addiction for more than 40 years, annual low-dose CT scans likely saved my life. In October 2024, my scan revealed a tumor ...

Roche is looking to a busy 2026 after 10 new molecules entered late-stage testing last year and as a potential launch of ...

The regulatory landscape for ANKTIVA saw critical developments regarding bladder cancer. ImmunityBio reported on January 20th that it held a Type B End-of-Phase meeting with the U.S. Food and Drug ...

Pancreatic cancer remains one of the deadliest cancers known, but two independent experimental therapies have now ...

Media Release Entered into strategic collaboration with Dr. Reddy's for commercialisation of eftilagimod alfa (efti) in all countries outside North America, Europe, Japan, and Greater ChinaIn January ...

Media ReleaseEntered into strategic collaboration with Dr. Reddy’s for commercialisation of eftilagimod alfa (efti) in all countries outside ...

Chugai files regulatory application with MHLF for additional indication of Tecentriq to treat adjuvant therapy for MRD-positive bladder cancer: Tokyo Thursday, January 29, 2026, 0 ...

Survivors of non-small cell lung cancer are at risk for both second primary lung cancers as well as non-lung secondary ...

A 25-year study led by the Barcelona Institute for Global Health finds that PM2.5 increases the risk of all lung cancer subtypes, while several gaseous pollutants are associated with non-small-cell ...